三种亚型无功能性垂体腺瘤中一种新的侵袭相关生物标志物
研究利用50例经蝶手术获取的无功能性垂体腺瘤(NFPA)组织,通过基因表达芯片和蛋白质组学分析整合筛选侵袭相关标志物,并在三种亚型中验证。发现EZR基因在三种亚型NFPA中侵袭性肿瘤表达高于非侵袭性肿瘤,且敲低EZR可抑制GH3细胞体外侵袭,提示EZR是NFPA侵袭的新生物标志物。
要点
- EZR在三种亚型NFPA中侵袭性肿瘤表达高于非侵袭性肿瘤。
- 敲低EZR可抑制GH3细胞体外侵袭。
- EZR有望作为NFPA治疗决策的指导标志物。
核心结论
- EZR是三种亚型无功能性垂体腺瘤中与侵袭相关的新生物标志物,也是治疗决策的有前景的指导。
研究设计与样本
- 研究使用50例经蝶手术获取的无功能性垂体腺瘤组织。
- 3例侵袭性和4例非侵袭性NFPA用于基因表达芯片分析。
- 5例侵袭性和4例非侵袭性NFPA用于蛋白质组学分析。
- 通过生物信息学整合转录组和蛋白质组数据鉴定侵袭相关生物标志物。
- 在三种亚型NFPA中通过定量实时逆转录聚合酶链反应和Western blot验证差异表达的候选标志物。
主要发现
- 生物信息学分析发现8个参与侵袭功能的基因。
- EZR基因被鉴定为三种亚型NFPA中新的侵袭相关生物标志物。
- 三种亚型NFPA中EZR表达水平在侵袭性肿瘤中高于非侵袭性肿瘤。
- 敲低EZR可抑制GH3细胞体外侵袭。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify biomarkers key to invasiveness of the 3 subtypes of nonfunctioning pituitary adenomas (NFPAs) and provide a guidance for therapeutic decision making and identification of potential adjuvant drugs. METHODS: Fifty NFPA tumor tissues obtained from transsphenoidal surgery were used in the study. Three invasive NFPAs and 4 noninvasive NFPAs were used for gene expression microarray analyses. In addition, there are 5 invasive NFPAs and 4 noninvasive NFPAs used for proteomic analyses. Invasive-related biomarkers were identified by bioinformatics analysis by integrating the transcriptomics and proteomics data sets. All 3 subtypes of NFPAs (null cell adenomas, oncocytomas, and gonadotroph adenomas) were used to validate differentially expressed candidate biomarkers by means of quantitative real-time reverse transcription polymerase chain reaction and Western blot. The level of EZR was downregulated in pituitary adenoma cell line GH3 to investigate the invasive effect of EZR on GH3 cells by using the RNA interference technique. RESULTS: Eight genes involved in the invasion function were found by bioinformatics analysis, and the EZR gene was identified as a novel invasive-related biomarker in the 3 subtypes of NFPAs. The expression level of EZR was found higher in terms of invasiveness than the noninvasive ones of the 3 subtypes of NFPAs. Moreover, the knockdown of EZR inhibited the invasion of GH3 cells in vitro. CONCLUSIONS: EZR is a novel biomarker in terms of invasion among the 3 subtypes of NFPAs, and it is a promising guide for therapeutic decision making as well.
引用
- Chen Y, Chuan HL, Yu SY, et al. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas. World Neurosurg. 2017. PMID: 28093347. doi:10.1016/j.wneu.2017.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。